[1] Storm DR,Rosenthal KS,Swanson PE.Polymyxin and related peptide antiibiotics[J].Annu Rev Biochem,1977,46:723-763. [2] Hu FP,Guo Y,Zhu DM,et al.Antimicrobial resistance profile of clinical isolates in hospitals across China:report from the CHINET Surveillance Program,2017[J].Chinese Journal of Infection and Chemotherapy(中国感染与化疗杂志),2018,18(3):241-251. [3] Chinese XDR Consensus Working Group,Guan XD,He LX,et al.Laboratory diagnosis,clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli:a Chinese conse-nsus statement[J].Clinical Microbiology and Infection,2016:22:S15-S25. [4] Tran TB,Velkov T,Nation RL,et al.Pharmacokinetics-pharmacodynamics of colistin and Polymyxin B:are we there yet?[J].Int J Antimicrob Agents,2016,48(6):592-597. [5] Chen Y,Mai SX,Wen XR,et al.Literature analysis of skin pigmentation in adult patients induced by polymyxin B[J].Chinese Journal of Drug Applic-ation and Monitoring(中国药物应用与监测),2019,16(3):161-164. [6] Mattos KPH,Cintra ML,Gouvea IR,et al.Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process[J].J Clin Pharm Ther,2017,42(5):573-578. [7] Bushby SR,Green AF.The release of histamine by polymyxin b and polymyxine[J].British Journal of Pharmacology and Chemotherapy,1955,10(2):215-219. [8] Yoshida M,Takshashi Y,Inoue S.Histamine induces melanogenesis and morphologic changes by protein kinase A activation via H2 receptors in human normal melanocytes[J].J Invest Dermatol,2000,114(2):334-342. [9] Slater D,Histologic diagnosis of inflammatory skin diseases An algorithmic method based on pattern analysis,3 rdedu[J].Histopathology,2005,47(6):707-708. [10] Zheng GH,Cao L,Che ZQ,et al.Polymyxin B-induced skin hyperpigmentation:a rare case report and literature review.[J].BMC pharmacology &toxicology,2018,19(1):41. [11] Knueppel RC,Rahimian J.Diffuse cutaneous hyperpingmentation due to tigecycline or polymyxin B[J].Clin Infect Dis,2007,45(1):136-138. [12] Kronenfeld MA,Thomas SJ,Turndorf H.Recurrence of neuromuscular blockade after reversalofvecuronium in a patient receiving polymyxin-amikacin sternal irrigation[J].Anesthesiology,1986 (65):93-94. [13] Lindesmith LA,Baines RD Jr,Bigelow DB,et al.Reversible respiratory paralysis associated with polymyxintherapy[J].Ann Intern Med,1968(68):318-327. [14] Fogdall RP,Miller RD.Prolongation of a pancuronium-induced neuro-muscular blockade by polymyxin B[J].Anesthesiology,1974 (40):84-87. [15] Gebbie D.Colistimethate and curare:a case report[J].Anesth Analg,1971 (50):109-111. [16] Zauder HL,Barton N,Bennett EJ,et al.Colistimethate as a cause of postoperative apnoea[J].Can AnaesthSoc J,1966 (13):607-610. [17] Justin R,LenhardT,Roger L,et al.Synergistic combinations of polymyxins[J].International Journal of Antimicrobial Agents,2016,48(6):241-244. [18] Liang BB,Wang R,Wang J,et al.Bibliometric analysis of polymyxin nephrotoxicity literature based on Web of Science[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2015,12(12):756-759. [19] Oliveir AM,Prado GVB,Costa SF,et al.Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity[J].Diagn MicrInfec Dis,2009,65(4):431-434. [20] Falagas ME,Rizos M,Bliziotis IA,et al.Toxicity after prolonged (more than four weeks) administration of intravenous colistin[J].BMC Infect Dis,2005(5):1. |